Nowadays, simultaneous inhibition of multiple targets through drug combination is an important anticancer strategy owing to the complex mechanism behind tumorigenesis. Recent studies have demonstrated that the inhibition of histone deacetylases (HDACs) will lead to compensated activation of a notorious cancer-related drug target, signal transducer and activator of transcription 3 (STAT3), in breast cancer through a cascade, which probably limits the anti-proliferation effect of HDAC inhibitors in solid tumors. By incorporating the pharmacophore of the HDAC inhibitor SAHA (vorinostat) into the STAT3 inhibitor pterostilbene, a series of potent pterostilbene hydroxamic acid derivatives with dual-target inhibition activity were synthesized. An excellent hydroxamate derivate, compound <b>14</b>, inhibited STAT3 (<i>K</i><sub>D</sub> = 33 nM) and HDAC (IC<sub>50</sub> = 23.15 nM) with robust potency <i>in vitro</i>. Compound <b>14</b> also showed potent anti-proliferation ability <i>in vivo</i> and <i>in vitro</i>. Our study provides the first STAT3 and HDAC dual-target inhibitor for further exploration.